Chemomab Therapeutics (CMMB) vs Kiora Pharmaceuticals (KPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiora Pharmaceuticals (KPRX) has outperformed Chemomab Therapeutics (CMMB) over the past year, losing 7.3% versus a loss of 60.3%. Over five years, CMMB leads with a -96.2% price change compared with -99.6% for KPRX. Kiora Pharmaceuticals is the larger company by market cap ($11.2 million vs $10.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMMB | KPRX |
|---|---|---|
| Share price | $1.39 | $2.53 |
| Market cap | $10.19M | $11.19M |
| 1-day change | +2.21% | 0.00% |
| YTD return | -15.76% | +28.43% |
| 1-year return | -60.29% | -7.33% |
| 5-year return | -96.18% | -99.64% |
| EPS (TTM) | $-1.04 | $-2.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.55 | $2.91 |
| 52-week low | $1.05 | $1.77 |
| Distance from 52-week high | -60.85% | -13.06% |
| Analyst consensus | none | none |
| Avg. price target upside | +259.71% | +374.31% |
| Average volume | 118.53K | 17.41K |
| Shares outstanding | 7.33M | 4.42M |
| Employees | — | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KPRX has outperformed CMMB by 53.0 percentage points over the past year.
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations
About Kiora Pharmaceuticals
KPRX stock →Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
CMMB vs KPRX FAQ
Which is bigger, Chemomab Therapeutics or Kiora Pharmaceuticals?
Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $11.19M compared with $10.19M for Chemomab Therapeutics (CMMB).
Which stock has performed better over the past year, CMMB or KPRX?
KPRX returned -7.33% over the past 12 months, compared with -60.29% for CMMB (price return, excluding dividends). Past performance does not predict future results.
Are Chemomab Therapeutics and Kiora Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.